Back to Search
Start Over
Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.
- Source :
-
BMC cardiovascular disorders [BMC Cardiovasc Disord] 2016 Jun 14; Vol. 16, pp. 138. Date of Electronic Publication: 2016 Jun 14. - Publication Year :
- 2016
-
Abstract
- Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a prognostic indicator.<br />Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF (n = 55), severe HF (n = 63), at 3 (n = 17) and 6 (n = 14) months post-LVAD and at LVAD explantation (n = 23), patients following HTx (n = 85) and healthy controls (n = 30).<br />Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001; controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower (3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation (40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD placement (76.5 % versus 95.0 % at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1 ng/ml post-HTx versus 28.2 ± 14 pre-HTx; p < 0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher galectin-3 levels (20.5 ± 8.8 ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3 (r (2) = 0.17, p < 0.0001).<br />Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3 might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.
- Subjects :
- Adult
Aged
Area Under Curve
Biomarkers blood
Biomechanical Phenomena
Blood Proteins
Coronary Artery Disease blood
Coronary Artery Disease etiology
Enzyme-Linked Immunosorbent Assay
Female
Galectins
Heart Failure blood
Heart Failure diagnosis
Heart Failure physiopathology
Humans
Male
Middle Aged
Predictive Value of Tests
Prosthesis Design
ROC Curve
Retrospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome
Galectin 3 blood
Heart Failure therapy
Heart Transplantation adverse effects
Heart-Assist Devices
Myocardial Contraction
Ventricular Function, Left
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2261
- Volume :
- 16
- Database :
- MEDLINE
- Journal :
- BMC cardiovascular disorders
- Publication Type :
- Academic Journal
- Accession number :
- 27301475
- Full Text :
- https://doi.org/10.1186/s12872-016-0298-z